
Conference Coverage
about 1 hour ago
IRA, 340B, Medicaid: The Policy Pressures on Community Oncologyabout 1 hour ago
Why Cancer Drug Access Takes Time: Scott A. Soefje, PharmD, MBAabout 1 hour ago
AI Innovation in Community Oncology Is Not All Hypeabout 2 hours ago
Caregiver Gaps Limit Access to New Therapies: Thomas LeBlanc, MD, MAabout 24 hours ago
Medicare Cap Eases Patient Costs as Negotiation Squeezes PracticesLatest Content

Drug Price Drives Value of MASH Therapies More Than Efficacy

IRA, 340B, Medicaid: The Policy Pressures on Community Oncology

Symptom Tracking May Aid Endometriosis Care, but Evidence Is Limited

"Pay for the Care, Not Only the Vial": The Hidden Costs of Cancer Care

AI Innovation in Community Oncology Is Not All Hype

Shorts










Center on Health Equity & Access
All News

Expert panel discussions covered AI and community access, chronic lymphocytic leukemia, myeloma, and breast and lung cancers.

Longer undetectable hepatitis D RNA on bulevirtide predicts durable suppression off therapy, but rebound and ALT flares rise, especially in cirrhosis.

Experts tackled CAR T access, trial equity, and overtreatment in breast cancer at an AJMC Institute for Value-Based Medicine event in San Francisco.

Systematic review finds combined immunonutrition (arginine, omega-3s, glutamine) in colorectal cancer surgery may cut surgical site infections, while single supplements show no benefit.

FACT Accreditation lets Tennessee Oncology bring community oncology CAR T-cell therapy closer to home, expanding access for non-Hodgkin lymphoma patients.

The analysis found a nonlinear association between systemic inflammation and overactive bladder, with stronger links at higher inflammation levels.

A real-world study found that adding a GLP-1 to SGLT2 inhibitor therapy was associated with lower kidney, cardiovascular, and mortality risks in CKD.

In experiments at MD Anderson, rising CD70 helps mantle cell lymphoma evade immunity; a CD70×CD3 bispecific restores T-cell killing and prolongs survival in resistant models.

The NPS index, ranging from –100 to +100, serves as a proxy for customers’ willingness to recommend products and services they themselves have used.

North Carolina experts discussed CLL, breast cancer, and myeloma treatments and how to expand access to complex cancer care beyond academic centers.





























